INDIANAPOLIS – Eli Lilly and Company (NYSE: NYSE:), a pharmaceutical giant with a market capitalization of over $700 billion and impressive gross profit margins of nearly 81%, has received approval from China’s National Medical (TASE:) Products Administration (NMPA) for Kisunla™ (donanemab-azbt), marking it as the fourth major market endorsement following the United States, Japan, and Great Britain. According to InvestingPro data, Lilly maintains a GOOD financial health score, positioning it strongly for this expansion. Kisunla is designed to treat adults with early symptomatic Alzheimer’s disease, including those with mild cognitive impairment (MCI) and mild dementia stages who have confirmed amyloid pathology.
In China, Alzheimer’s disease prevalence is significant, affecting nearly 6% of the population over 65, with projections suggesting an increase to 11% by 2050. The approval of Kisunla, which targets amyloid plaque buildup in the brain, provides a new therapeutic option for managing the disease. With revenue growth of 27% over the last twelve months and strong earnings forecasts, Lilly appears well-positioned to capitalize on this market opportunity.
The TRAILBLAZER-ALZ 2 Phase 3 clinical study underpins the NMPA’s approval. This study observed that Kisunla significantly slowed the progression of Alzheimer’s disease in participants, particularly those less advanced in the disease. Patients exhibited a 35% slower decline in cognitive and daily function compared to those on placebo. Additionally, Kisunla demonstrated a reduction in amyloid plaques by up to 84% over 18 months, with 66% of patients achieving plaque clearance at one year.
Despite these promising results, Kisunla is associated with potential side effects, such as amyloid-related imaging abnormalities (ARIA), which can include temporary brain swelling or bleeding, and infusion-related reactions. However, ARIA often presents without symptoms and can typically be monitored and managed with MRI scans.
Kisunla is administered intravenously every four weeks, with a dosing regimen that may allow for treatment discontinuation once amyloid plaques are removed, potentially reducing treatment costs and frequency of infusions.
The approval of Kisunla in China is based on a press release statement from Eli Lilly and Company and offers a new avenue for addressing the challenges of Alzheimer’s disease in a population with a growing prevalence of this condition. For investors seeking deeper insights into Lilly’s growth potential and comprehensive analysis, InvestingPro offers exclusive access to 15+ additional ProTips and a detailed Pro Research Report, helping you make informed investment decisions in the pharmaceutical sector.
In other recent news, pharmaceutical giant Eli Lilly and Innovent Biologics have announced an agreement granting Innovent exclusive rights to import, market, distribute, and promote Lilly’s cancer drug Jaypirca® in Mainland China. The partnership aims to address unmet clinical needs in the treatment of hematologic cancers and expand patient access to innovative therapies. In other developments, Eli Lilly’s weight loss drug Manjaro is gaining preference over Novo Nordisk (NYSE:)’s Wegovy among UK customers, indicating a significant shift in the UK’s weight loss drug market. Bernstein analysts have recognized Eli Lilly as a key player in the expanding global obesity drug market, projected to reach $95 billion by 2030, and maintained an Outperform rating on the company. Additionally, Eli Lilly’s drug Omvoh is nearing approval by the European Union for the treatment of Crohn’s disease, according to the European Medicines Agency’s Committee for Medicinal Products for Human Use. These are some of the recent developments in Eli Lilly’s journey.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
